Wolfe Research Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $42
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Andy Chen initiates coverage on Insmed (NASDAQ:INSM) with an Outperform rating and a price target of $42.

February 15, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wolfe Research has initiated coverage on Insmed with an Outperform rating and set a price target of $42.
The initiation of coverage by Wolfe Research with an Outperform rating and a price target significantly above the current trading price is likely to be viewed positively by the market. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100